Besançon

Futó vizsgálatok

• Fut, nem toboroz

  PRostate Olaparib Real World Evidence Study

  NCT06031805· Forrás

• Fut, nem toboroz

  National Acalabrutinib Observational Study

  NCT05437250· Forrás

• Fut, nem toboroz

  Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

  NCT04784715· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

  NCT04550260· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

  NCT04494425· 3. fázis· Forrás

• Fut, nem toboroz

  To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

  NCT03330847· 2. fázis· Forrás

• Fut, nem toboroz

  Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

  NCT03212404· 1. fázis· Forrás

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK

  NCT04532645· Forrás